Nwam LLC Has $1.34 Million Position in Natera, Inc. $NTRA

Nwam LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 31.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,681 shares of the medical research company’s stock after selling 2,997 shares during the period. Nwam LLC’s holdings in Natera were worth $1,336,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the period. Wellington Management Group LLP grew its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new position in shares of Natera in the fourth quarter worth $372,398,000. JPMorgan Chase & Co. increased its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after acquiring an additional 673,315 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. This represents a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 178,872 shares of company stock worth $39,627,696. Corporate insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. The Goldman Sachs Group began coverage on Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective for the company. BTIG Research set a $275.00 target price on Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. William Blair started coverage on Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. Barclays reduced their price target on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. Finally, Royal Bank Of Canada initiated coverage on Natera in a report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $267.83.

Natera Stock Up 1.7%

NASDAQ:NTRA opened at $277.37 on Thursday. The company’s 50 day moving average is $231.43 and its 200-day moving average is $219.80. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The firm has a market cap of $39.72 billion, a price-to-earnings ratio of -170.17 and a beta of 1.51.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.